Cost-effectiveness of a smoking cessation program after myocardial infarction

Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT 06510.

OBJECTIVES. The purpose of this study was to evaluate the cost-effectiveness of a smoking cessation program initiated after acute myocardial infarction. BACKGROUND. The value of allocating health care resources to smoking cessation programs after myocardial infarction has not been compared with the value of other currently accepted interventions. METHODS. A model was developed to examine the cost-effectiveness of a recently reported smoking cessation program after an acute myocardial infarction. The cost was estimated by considering the resources necessary to implement the program, and the effectiveness was expressed as discounted years of life saved. Years of life saved were estimated by modeling life expectancy using a single declining exponential approximation of life expectancy based on data from published reports. RESULTS. The cost-effectiveness of the nurse-managed smoking cessation program was estimated to be $220/year of life saved. In a one-way sensitivity analysis, the cost-effectiveness of the program remained < $20,000/year of life saved if the program decreased the smoking rate by only 3/1,000 smokers (baseline assumption 26/100 smokers), or if the program cost as much as $8,840/smoker (baseline assumption $100). In a two-way sensitivity analysis, even if the cost of the program were as high as $2,000/participant, the cost-effectiveness of the program would be < $10,000/year of life saved so long as the program helped an additional 12 smokers quit for every 100 enrolled. CONCLUSIONS. Over a wide range of estimates of costs and effectiveness, a nurse-managed smoking cessation program after acute myocardial infarction is an extremely cost-effective intervention. This program is more cost-effective than beta-adrenergic antagonist therapy after myocardial infarction.

This article has been cited by other articles:

				E. T. Ronckers, W. Groot, and A.J.H.A. Ament Systematic Review of Economic Evaluations of Smoking Cessation: Standardizing the Cost-Effectiveness Med Decis Making, July 1, 2005; 25(4): 437 - 448. [Abstract] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				H. M. Krumholz, W. S. Weintraub, W. D. Bradford, P. A. Heidenreich, D. B. Mark, and A. D. Paltiel Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it? J. Am. Coll. Cardiol., August 21, 2002; 40(4): 603 - 615. [Full Text] [PDF]

				C. Mannheimer, P. Camici, M.R. Chester, A. Collins, M. DeJongste, T. Eliasson, F. Follath, I. Hellemans, J. Herlitz, T. Luscher, et al. The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina Eur. Heart J., March 1, 2002; 23(5): 355 - 370. [Full Text] [PDF]

				S. C. Smith Jr, S. N. Blair, R. O. Bonow, L. M. Brass, M. D. Cerqueira, K. Dracup, V. Fuster, A. Gotto, S. M. Grundy, N. H. Miller, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update: A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology Circulation, September 25, 2001; 104(13): 1577 - 1579. [Full Text] [PDF]

				N. A Rigotti; and N. A Rigotti; II. Smoking cessation in the hospital setting---a new opportunity for managed care. Introduction Tob. Control, March 1, 2000; 9(90001): i54 - 54. [Full Text] [PDF]

				P. Stone A brief smoking cessation intervention for adults in hospital was cost effective Evid. Based Nurs., April 1, 1999; 2(2): 58 - 58. [Full Text]

				J. D. Corson, C. R. Mohan, J. J. Hoballah, W. J. Sharp, and T. F. Kresowik Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference? Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1996; 9(1): 75 - 94. [PDF]